138 related articles for article (PubMed ID: 7787254)
1. Biological activity of human N-ras and K-ras genes containing the Asn17 dominant negative mutation.
Kaplan JB
Oncol Res; 1994; 6(12):611-5. PubMed ID: 7787254
[TBL] [Abstract][Full Text] [Related]
2. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
[TBL] [Abstract][Full Text] [Related]
3. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y].
Yokoyama T
Hokkaido Igaku Zasshi; 1995 May; 70(3):459-71. PubMed ID: 7590597
[TBL] [Abstract][Full Text] [Related]
4. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
[TBL] [Abstract][Full Text] [Related]
5. H-, K- and N-Ras inhibit myeloid leukemia cell proliferation by a p21WAF1-dependent mechanism.
Delgado MD; Vaqué JP; Arozarena I; López-Ilasaca MA; Martínez C; Crespo P; León J
Oncogene; 2000 Feb; 19(6):783-90. PubMed ID: 10698496
[TBL] [Abstract][Full Text] [Related]
6. Oncogenic activation of human R-ras by point mutations analogous to those of prototype H-ras oncogenes.
Saez R; Chan AM; Miki T; Aaronson SA
Oncogene; 1994 Oct; 9(10):2977-82. PubMed ID: 8084601
[TBL] [Abstract][Full Text] [Related]
7. Ras-15A protein shares highly similar dominant-negative biological properties with Ras-17N and forms a stable, guanine-nucleotide resistant complex with CDC25 exchange factor.
Chen SY; Huff SY; Lai CC; Der CJ; Powers S
Oncogene; 1994 Sep; 9(9):2691-8. PubMed ID: 8058333
[TBL] [Abstract][Full Text] [Related]
8. A novel human ERK phosphatase regulates H-ras and v-raf signal transduction.
Shin DY; Ishibashi T; Choi TS; Chung E; Chung IY; Aaronson SA; Bottaro DP
Oncogene; 1997 Jun; 14(22):2633-9. PubMed ID: 9178761
[TBL] [Abstract][Full Text] [Related]
9. A role for Ras in v-Crk transformation.
Greulich H; Hanafusa H
Cell Growth Differ; 1996 Nov; 7(11):1443-51. PubMed ID: 8930393
[TBL] [Abstract][Full Text] [Related]
10. Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival.
Xin H; Geng Y; Pramanik R; Choubey D
J Cell Biochem; 2003 Jan; 88(1):191-204. PubMed ID: 12461788
[TBL] [Abstract][Full Text] [Related]
11. trans-Dominant suppressor mutations of the H-ras oncogene.
Ogiso Y; Gutierrez L; Wrathall LS; Lu YY; Blair DG; Clanton DJ; Hwang YW; Shih TY
Cell Growth Differ; 1990 May; 1(5):217-24. PubMed ID: 2150753
[TBL] [Abstract][Full Text] [Related]
12. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation.
Du Villard JA; Wicker R; Crespo P; Russo D; Filetti S; Gutkind JS; Sarasin A; Suárez HG
Oncogene; 2000 Oct; 19(42):4896-905. PubMed ID: 11039907
[TBL] [Abstract][Full Text] [Related]
13. Ras- and Raf-mediated regulation of transforming growth factor beta 1 gene expression by ligands of tyrosine kinase receptors in PC12 cells.
Cosgaya JM; Aranda A
Oncogene; 1996 Jun; 12(12):2651-60. PubMed ID: 8700524
[TBL] [Abstract][Full Text] [Related]
14. Ornithine decarboxylase induction in transformation by H-Ras and RhoA.
Shantz LM; Pegg AE
Cancer Res; 1998 Jul; 58(13):2748-53. PubMed ID: 9661886
[TBL] [Abstract][Full Text] [Related]
15. Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant.
Rapp UR; Troppmair J; Beck T; Birrer MJ
Oncogene; 1994 Dec; 9(12):3493-8. PubMed ID: 7970709
[TBL] [Abstract][Full Text] [Related]
16. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
[TBL] [Abstract][Full Text] [Related]
17. Regulation of myeloid cell growth by distinct effectors of Ras.
Matsuguchi T; Kraft AS
Oncogene; 1998 Nov; 17(21):2701-9. PubMed ID: 9840934
[TBL] [Abstract][Full Text] [Related]
18. Synergistic activation of c-fos promoter activity by Raf and Ral GDP dissociation stimulator.
Okazaki M; Kishida S; Hinoi T; Hasegawa T; Tamada M; Kataoka T; Kikuchi A
Oncogene; 1997 Feb; 14(5):515-21. PubMed ID: 9053849
[TBL] [Abstract][Full Text] [Related]
19. Cellular ras gene activity is required for full neoplastic transformation by the large tumor antigen of SV40.
Raptis L; Brownell HL; Corbley MJ; Wood KW; Wang D; Haliotis T
Cell Growth Differ; 1997 Aug; 8(8):891-901. PubMed ID: 9269898
[TBL] [Abstract][Full Text] [Related]
20. Retroviral gene transfer of dominant negative raf-1 mutants suppresses ha-ras-induced transformation and delays tumor formation.
Heinicke T; Radziwill G; Nawrath M; Rommel C; Pavlovic J; Moelling K
Cancer Gene Ther; 2000 May; 7(5):697-706. PubMed ID: 10830717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
